419 results on '"Mackie, Sarah L"'
Search Results
2. Polymyalgia rheumatica shows metabolomic alterations that are further altered by glucocorticoid treatment: Identification of metabolic correlates of fatigue
3. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study
4. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
5. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases
6. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
7. Polymyalgia rheumatica
8. Test-retest reliability of pain VAS/NRS, stiffness VAS/NRS, HAQ-DI and mHAQ in polymyalgia rheumatica: An OMERACT study
9. A methodological framework for AI-assisted diagnosis of active aortitis using radiomic analysis of FDG PET–CT images: Initial analysis
10. Imaging of giant cell arteritis – recent advances
11. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study
12. Estimating overdiagnosis in giant cell arteritis diagnostic pathways using genetic data: genetic association study.
13. Micro-RNA content of circulating extracellular vesicles in early rheumatoid arthritis as biomarkers and mediators of methotrexate efficacy.
14. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
15. P186 Impact of glucocorticoids on appearance and sense of self in rheumatic diseases
16. Genetically predicted serum urate levels have no causal role on depression or other psychiatric disorders
17. Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective
18. Treatment of polymyalgia rheumatica: British Society for Rheumatology guideline scope
19. Tocilizumab and glucocorticoids for giant cell arteritis: the learning curve
20. Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO)
21. Practice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines
22. Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO).
23. The Patientsʼ Perspective of Important Glucocorticoid Effects: A Nominal Group Study Among Patients With Systemic Lupus Erythematosus and Myositis
24. Jaw claudication and jaw stiffness in giant cell arteritis: secondary analysis of a qualitative research dataset
25. Genetically proxied IL-1 receptor antagonism and risk of polymyalgia rheumatica
26. Life after tocilizumab given for giant cell arteritis: a patient survey and argument for re-treatment.
27. Characteristics of patients with giant cell arteritis who experience visual symptoms
28. Should race be considered in diagnosing giant cell arteritis? – Authors' reply
29. Game-changing therapies for people with giant cell arteritis?
30. Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
31. Jaw claudication and jaw stiffness in giant cell arteritis: secondary analysis of a qualitative research dataset.
32. Treatment of polymyalgia rheumatica: British Society for Rheumatology guideline scope.
33. Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
34. Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment–specific patient-reported outcome measure.
35. Giant cell arteritis can occur in people of colour
36. P114 Exploring micro-RNA content of circulating extracellular vesicles as biomarkers in early rheumatoid arthritis
37. OA32 Jaw claudication - does the textbook description need updating?
38. E013 Co-production of a quality improvement project to address glucocorticoid toxicity
39. E038 A common measure of the impact of glucocorticoids in patients with inflammatory and autoimmune conditions - the Steroid PRO: A cross-cultural validation study with Rasch models
40. P203 Comparison of coding of giant cell arteritis in primary and secondary care records: an observational feasibility study
41. OA34 To determine the diagnostic test accuracy of different ultrasound diagnostic criteria in the diagnosis of giant cell arteritis: a secondary data analysis
42. An Automated Method for Artifical Intelligence Assisted Diagnosis of Active Aortitis Using Radiomic Analysis of FDG PET-CT Images
43. Common co-morbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank.
44. Consensus on the Definitions and Descriptions of the Domains of the Omeract Core Outcome Set for Shared Decision Making Interventions in Rheumatology Trials
45. Angiogenesis and Giant Cell Arteritis
46. Angiotensin receptor blockade is associated with increased risk of giant cell arteritis
47. A Survey of Glucocorticoid Adverse Effects and Benefits in Rheumatic Diseases: The Patient Perspective
48. Polymyalgia rheumatica
49. Angiotensin receptor blockade is associated with increased risk of giant cell arteritis.
50. Developing consensus in Histopathology: the role of the Delphi method
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.